Invention Grant
- Patent Title: Injectable flowable composition comprising buprenorphine
-
Application No.: US15820048Application Date: 2017-11-21
-
Publication No.: US10558394B2Publication Date: 2020-02-11
- Inventor: Richard L. Norton , Andrew Watkins , Mingxing Zhou
- Applicant: INDIVIOR UK LIMITED
- Applicant Address: GB Hull
- Assignee: INDIVIOR UK LIMITED
- Current Assignee: INDIVIOR UK LIMITED
- Current Assignee Address: GB Hull
- Agency: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
- Agent Edward D. Grieff
- Priority: GB1009549.5 20100608
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K31/00 ; A61K31/485 ; A61K47/22 ; A61K31/4748 ; A61K47/34 ; G06F3/06 ; G06F16/11 ; G06F9/48

Abstract:
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
Public/Granted literature
- US20180157440A1 INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE Public/Granted day:2018-06-07
Information query